North Star Investment Management’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.7K Hold
330
– – ﹤0.01% 947
2026
Q1
$15.9K Hold
330
– – ﹤0.01% 936
2025
Q4
$23K Hold
330
– – ﹤0.01% 822
2025
Q3
$9.24K Hold
330
– – ﹤0.01% 925
2025
Q2
$6.84K Hold
330
– – ﹤0.01% 956
2025
Q1
$5.71K Hold
330
– – ﹤0.01% 959
2024
Q4
$8.95K Sell
330
-650
-66% -$23.1K ﹤0.01% 888
2024
Q3
$43K Hold
980
– – ﹤0.01% 627
2024
Q2
$38.5K Buy
980
+100
+11% +$4.11K ﹤0.01% 633
2024
Q1
$37.7K Hold
880
– – ﹤0.01% 653
2023
Q4
$35.9K Hold
880
– – ﹤0.01% 643
2023
Q3
$44.4K Buy
+880
New +$28.4K ﹤0.01% 609

Other funds holding GPCR

North Star Investment Management's GPCR Position: Q2 2026 in Review

North Star Investment Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 330 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

North Star Investment Management first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $44.4K in Q3 2023. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • North Star Investment Management held 330 shares of Structure Therapeutics worth $17.7K as of Q2 2026.
  • North Star Investment Management left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of North Star Investment Management's portfolio in Q2 2026, its #947 holding.
  • North Star Investment Management first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • North Star Investment Management's Structure Therapeutics position peaked at $44.4K in Q3 2023.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.